Literature DB >> 32546577

Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.

Geneviève Deblois1,2,3, Seyed Ali Madani Tonekaboni1,4, Giacomo Grillo1, Constanza Martinez5, Yunchi Ingrid Kao1,4, Felicia Tai1,4, Ilias Ettayebi1,4, Anne-Marie Fortier5, Paul Savage5, Alexandra N Fedor1,4, Xiaojing Liu6, Paul Guilhamon1, Evelyne Lima-Fernandes1,4,7, Alex Murison1, Hellen Kuasne5, Wail Ba-Alawi1,4,8, David W Cescon1, Cheryl H Arrowsmith1,4,7, Daniel D De Carvalho1,4, Benjamin Haibe-Kains1,4,8, Jason W Locasale6, Morag Park5, Mathieu Lupien9,4,10.   

Abstract

Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant triple-negative breast cancer (TNBC). This is enabled by an epigenetic state adapted to taxane-induced metabolic stress, where DNA hypomethylation over loci enriched in transposable elements (TE) is compensated by large chromatin domains of H3K27me3 to warrant TE repression. This epigenetic state creates a vulnerability to epigenetic therapy against EZH2, the H3K27me3 methyltransferase, which alleviates TE repression in taxane-resistant TNBC, leading to double-stranded RNA production and growth inhibition through viral mimicry response. Collectively, our results illustrate how epigenetic states over TEs promote cancer progression under treatment and can inform about vulnerabilities to epigenetic therapy. SIGNIFICANCE: Drug-resistant cancer cells represent a major barrier to remission for patients with cancer. Here we show that drug-induced metabolic perturbation and epigenetic states enable evasion from the viral mimicry response induced by chemotherapy in TNBC. These epigenetic states define a vulnerability to epigenetic therapy using EZH2 inhibitors in taxane-resistant TNBC.See related commentary by Janin and Esteller, p. 1258.This article is highlighted in the In This Issue feature, p. 1241. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32546577     DOI: 10.1158/2159-8290.CD-19-1493

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  26 in total

1.  Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis.

Authors:  Dalang Fang; Yanting Li; Yanghong Li; Yongcheng Chen; Qianfang Huang; Zhizhai Luo; Jinghua Chen; Yingjin Li; Zaizhi Wu; Yuanlu Huang; Yanfei Ma
Journal:  Gland Surg       Date:  2022-06

Review 2.  Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.

Authors:  Jae Young So; Joyce Ohm; Stan Lipkowitz; Li Yang
Journal:  Pharmacol Ther       Date:  2022-07-21       Impact factor: 13.400

3.  Building the Canadian Bladder Cancer Research Network (CBCRN): Progress during a pandemic.

Authors:  Peter C Black; Nimira Alimohamed; Wassim Kassouf; John L Gore; Kathy D McCoy; Brad H Nelson; Daniel D De Carvalho; Rodney J Ouellette; Ferg Devins; Tony Cornacchia; D Robert Siemens; David M Berman; Srikala S Sridhar; Girish Kulkarni
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

4.  DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.

Authors:  Lian Zhang; Hong-Tao Li; Rachel Shereda; Qianjin Lu; Daniel J Weisenberger; Casey O'Connell; Keigo Machida; Woojin An; Heinz-Josef Lenz; Anthony El-Khoueiry; Peter A Jones; Minmin Liu; Gangning Liang
Journal:  Cancer Lett       Date:  2022-09-08       Impact factor: 9.756

Review 5.  Toward a Mechanistic Understanding of Poly- and Perfluoroalkylated Substances and Cancer.

Authors:  Raya I Boyd; Saeed Ahmad; Ratnakar Singh; Zeeshan Fazal; Gail S Prins; Zeynep Madak Erdogan; Joseph Irudayaraj; Michael J Spinella
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

Review 6.  Nutritional Epigenetics in Cancer.

Authors:  Maria J Barrero; Paloma Cejas; Henry W Long; Ana Ramirez de Molina
Journal:  Adv Nutr       Date:  2022-10-02       Impact factor: 11.567

Review 7.  The interplay between DNA and histone methylation: molecular mechanisms and disease implications.

Authors:  Yinglu Li; Xiao Chen; Chao Lu
Journal:  EMBO Rep       Date:  2021-04-12       Impact factor: 8.807

8.  The Bidirectional Relationship Between Cancer Epigenetics and Metabolism.

Authors:  Luke T Izzo; Hayley C Affronti; Kathryn E Wellen
Journal:  Annu Rev Cancer Biol       Date:  2020-11-30

Review 9.  Endogenous retroviruses in the origins and treatment of cancer.

Authors:  Natasha Jansz; Geoffrey J Faulkner
Journal:  Genome Biol       Date:  2021-05-10       Impact factor: 13.583

10.  H3K27me3 conditions chemotolerance in triple-negative breast cancer.

Authors:  Justine Marsolier; Pacôme Prompsy; Adeline Durand; Anne-Marie Lyne; Camille Landragin; Amandine Trouchet; Sabrina Tenreira Bento; Almut Eisele; Sophie Foulon; Léa Baudre; Kevin Grosselin; Mylène Bohec; Sylvain Baulande; Ahmed Dahmani; Laura Sourd; Eric Letouzé; Anne-Vincent Salomon; Elisabetta Marangoni; Leïla Perié; Céline Vallot
Journal:  Nat Genet       Date:  2022-04-11       Impact factor: 41.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.